Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 6, 2006, Pages 1361-1366

  Mlynarska, Agata ^a   Waszyrowski, T ^a   Kasprzak, J D ^b  

^a Karol Jonscher hospital Lodz   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Genetics; Myocardial infarction; Plasminogen activators inhibitor type 1

Indexed keywords

ACETYLSALICYLIC ACID; GUANINE; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ALLELE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYTIC THERAPY; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REBOUND;

AGED; FEMALE; FIBRINOLYTIC AGENTS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 33646811482     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01990.x     Document Type: Article

References (38)

1. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-7.
2. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-90.
3. Goto S, Kawai Y, Handa S, Abe S, Takahashi E, Watanabe K, Hori S, Ikeda Y. Serial changes in plasma concentration of plasminogen activator inhibitor-1 before and serially after thrombolytic therapy for acute myocardial infarction. Cardiology 1993; 82: 280-5.
4. Genser N, Lechleitner P, Maier J, Dienstl F, Artner-Dworzak E, Puschendorf B, Mair J. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin Chem 1998; 44: 209-14.
5. Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis. Thromb Res 2001; 103: S1-S5.
6. Li XN, Grenett HE, Benza RL, Demissie S, Brown SL, Tabengwa EM, Gianturco SH, Bradley WA, Fless GM, Booyse FM. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 3215-23.
7. Humphries SE, Panahloo A, Montgomery HE, Green F, Yudkin J. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Thromb Haemost 1997; 78: 457-61.
8. Juhan-Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, Hawe E, Boquist S, Tornvall P, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: The HIFMECH study. J Thromb Haemost 2003; 1: 2322-9.
9. Panahloo A, Mohamed-Ali V, Gray RP, Humphries SE, Yudkin JS. Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: The role of acute phase reactants, insulin-like molecules and promoter (4G/ 5G) polymorphism in the PAI-1 gene. Atherosclerosis 2003; 168: 297 -304.
10. Muntner P, He J, Roccella EJ, Whelton PK. The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension 2002; 39: 897-902.
11. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) (Adult Treatment Panel III) JAMA 2001; 285: 2486-97.
12. Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d'Addedda M, Di Minno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77: 605-6.
13. Rosner B. Fundamentals of Biostatistics, 5th edn. Pacific Grove, CA, USA: Duxbury Press, 1999.
14. Lachin JM. Biostatistical Methods. The Assessment of Relative Risks. New York, NY, USA: Wiley & Sons, 2000.
15. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
16. Huber K, Resch I, Stefenelli T, Lang I, Probst P, Kaindl F, Binder BR. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemost 1990; 63: 336-9.
17. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-63.
18. ECAT angina pectoris study: Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
19. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 1993; 72: 413-21.
20. Gray RP, Yudkin JS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor ? Br Heart J 1993; 70: 530-6.
21. Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991; 65: 275-9.
22. Francis CW, Marder VJ. Physiologic regulation and pathologic disorders of fibrinolysis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA, USA: Lippincott Co., 1994: 1076 -103.
23. Munkvad S, Gram J, Jespersen J. Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue- type plasminogen activator. A randomized, placebo-controlled study. Scand J Clin Lab Invest 1991; 51: 581-90.
24. Fujii S, Sawa H, Saffitz JE, Lucore CL, Sobel BE. Induction of endothelial cell expression of the plasminogen activator inhibitor type 1 gene by thrombosis in vivo. Circulation 1992; 86: 2000-10.
25. Cockell KA, Ren S, Sun J, Angel A, Shen GX. Effect of thrombin on release of plasminogen activator inhibitor-1 from cultured primate arterial smooth muscle cells. Thromb Res 1995; 77: 119-31.
26. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7.
27. Lew AS, Berberian L, Cercek B, Lee S, Shah PK, Ganz W. Elevated serum D dimer: A degradation product of cross-linked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction. J Am Coll Cardiol 1986; 7: 1320-4.
28. Olman MA, Hagood JS, Simmons WL, Fuller GM, Vinson C, White KE. Fibrin fragment induction of plasminogen activator inhibitor transcription is mediated by activator protein-1 through a highly conserved element. Blood 1999; 94: 2029-38.
29. Lip GY, Lydakis C, Nuttall SL, Landray MJ, Watson RD, Blann AD. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute myocardial infarction. J Intern Med 2000; 248: 316-8.
30. Huber K. Plasminogen activator inhibitor type-1 (part one): Basic mechanisms, regulation, and role for thromboembolic disease. J Thromb Thrombolysis 2001; 11: 183-93.
31. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E, Pennelli O, Di Minno G. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 152-6.
32. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis. Thromb Haemost 1998; 80: 1029-30.
33. Doggen CJ, Bertina RM, Cats VM, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999; 82: 115-20.
34. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, Ferrieres J, Evans A, Amouyel P, Poirier O, Cambien F, Juhan-Vague I. Five frequent polymorphisms of the PAI-1 gene: Lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997; 17: 851-8.
35. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18: 20-6.
36. Chen YQ, Sloan-Lancaster J, Berg DT, Richardson MA, Grinnell B, Tseng-Crank J. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Thromb Haemost 2001; 86: 1563-72.
37. Johnsen SA, Subramaniam M, Janknecht R, Spelsberg TC. TGFbeta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses. Oncogene 2002; 21: 5783-90.
38. Stroschein SL, Wang W, Luo K. Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor beta-induced smad-dependent transcriptional activation. J Biol Chem 1999; 274: 9431-41.